Hengrui Highlights Innovative Oncology Research at ESMO Congress 2026
Hengrui Showcases Groundbreaking Oncology Research at ESMO 2026
The European Society for Medical Oncology (ESMO) Congress 2026, recently held in Madrid, served as a significant platform for Hengrui Pharma to present its latest innovations in the field of oncology. Hengrui, a prominent player in the Chinese pharmaceutical market, made headlines with a record-setting 64 research presentations, underscoring the company's research strength and potential impact on global oncology treatments.
Highlighting Chinese Innovations on a Global Stage
Hengrui has long been a champion of significant advancements in cancer treatment. At this year’s ESMO Congress, the company's efforts garnered further recognition as numerous oncology studies were accepted for presentation. Among the showcased research were three
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.